Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results-Reference-Cited by-同舟云学术

Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

Published:2016-05 Issue:5 Volume:6 Page:e425-e425
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Stefoni V,Casadei B,Bottelli C,Gaidano G,Ciochetto C,Cabras M G,Ansuinelli M,Argnani L,Broccoli A,Gandolfi L,Pellegrini C,Zinzani P L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201629.pdf

Reference18 articles.

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 2453–2463.

2. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54–58.

3. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 804–810.

4. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431.

5. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119–3126.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioligand Therapy in Lymphoma;PET Clinics;2024-10

2. Radioimmunotherapy;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

3. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

4. 90Y-ibritumomab tiuxetan in B-cell non-Hodgkin lymphomas: Real-world data from the United Arab Emirates;Advances in Radiation Oncology;2021-12

5. Theranostics of Hematologic Disorders;Nuclear Medicine and Immunology;2021-11-25